Differentiated approach to metformin therapy in newly diagnosed type 2 diabetes mellitus from the perspective of pharmacogenetics


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background. Metformin remains the first-line drug for newly diagnosed type 2 diabetes mellitus (T2DM). It has been shown that common genetic variants affect the glycemic response to metformin, which explains up to 34% of the variability in the decrease in glycated hemoglobin (HbA1c) during treatment with this drug. Further studies are required to clarify the effect of the KCNJ11 rs5219 and TCF7L2 rs7903146 variants on the individual therapeutic effect of metformin and to determine the significance of genotyping results for these polymorphisms in the development of a differentiated approach to therapy in patients with newly diagnosed T2DM. Objective. Evaluation of the role of KCNJ11 rs5219 and TCF7L2 rs7903146 polymorphisms in the formation of an individual response to metformin therapy in patients with newly diagnosed T2DM. Methods. The prospective cohort study included 77 patients with newly diagnosed T2DM who received initial metformin therapy. The dynamics of the main indicators of glycemic control and body mass index (BMI) was assessed over 6 months of treatment. All patients were genotyped for the KCNJ11 rs5219 (C>T) and TCF7L2 rs7903146 (C>T) polymorphisms using the real-time polymerase chain reaction technique. Results. After 6 months of metformin treatment, the KCNJ11 rs5219 variant was associated with significantly greater reductions in BMI, fasting blood glucose, and HbA1c in newly diagnosed T2DM (P<0.05). No association was found between the carriage of the TCF7L2 rs7903146 polymorphism and the individual response to metformin in the studied cohort of patients. Conclusion. Our results show that patients with newly diagnosed T2DM with the KCNJ11 rs5219 polymorphism are more susceptible to metformin therapy than carriers of the wild genotype. No data have been obtained on the effect of the TCF7L2 rs7903146polymorphism on the therapeutic effect of metformin in patients with newly diagnosed T2DM.

Texto integral

Acesso é fechado

Sobre autores

Polina Shorokhova

North-Western State Medical University n.a. I.I. Mechnikov

Email: poliamina@gmail.com
Endocrinologist, Postgraduate Student, Department of Endocrinology n.a. Academician V.G. Baranov Saint Petersburg, Russia

V. Baranov

North-Western State Medical University n.a. I.I. Mechnikov

Department of Endocrinology n.a. Academician V.G. Baranov Saint Petersburg, Russia

Bibliografia

  1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation, 2019. URL: https://www.diabetesatlas.org.
  2. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4-102. [Dedov I.I., Shestakova M.V, Mayorov A.Yu., et al. Diabetes mellitus type 2 in adults. Sakharnyi diabet=Diabetes mellitus. 2020;23(2S):4-102. (In Russ.)]. doi: 10.14341/DM12507.
  3. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl. 1):S111-24. Doi: 10.2337/ dc21-S009.
  4. Дедов И.И., Шестакова М.В., Викулова О.К и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета на 01.01.2021. Сахарный диабет 2021;24(3):204-21.
  5. Zeitler P., Hirst K., et al.: TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247-56. Doi: 10.1056/ NEJMoa1109333.
  6. Becker M.L., Pearson E.R., Tkac I. Pharmacogenetics of oral antidiabetic drugs. !nt J Endocrinol. 2013;2013:686315. doi: 10.1155/2013/686315.
  7. Сычев Д.А., Шуев Г.Н., Торбенков Е.С., Адриянова М.А. Персонализированная медицина: взгляд клинического фармаколога. Consilium Medicum. 2017;19(1):61-8.
  8. Баранов В.Л., Ворохобина Н.В., Абулула М. и др. Клиническое значение полиморфизма rs622342 гена SLC22A1 у пациентов с сахарным диабетом 2 типа при терапии метфор-мином. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2015;7(1):22-7
  9. Tkac I., Klimcakova L., M., et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diab Obes Metab. 20I3;I5(2):I89-9I. doi: 10.1111/j.1463-1326.2012.01691.x.
  10. Ashcroft F.M., Rorsman P K(ATP) channels and islet hormone secretion: new insights and controversies. Nat Rev Endocrinol. 2013;9(11):660-69. doi: 10.1038/nrendo.2013.166.
  11. Wang D.D., Chen X., Yang Y, Liu C.X. Association of Kir6.2 gene rs5219 variation with type 2 diabetes: A meta-analysis of 21,464 individuals. Prim Care Diab. 2018;12(4):345-53. Foi: 10.1016/j.pcd.2018.03.004.
  12. Florez J.C., Jablonski K.A., Kahn S.E., et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diab. 2007;56(2):531-36. doi: 10.2337/db06-0966.
  13. Лапик И.А., Гаппарова К.М., Шарафетди-нов Х.Х. и др. Оценка эффективности персонализированной терапии больных ожирением и сахарным диабетом 2 типа, назначенной на основе изучения полиморфизма rs5219 гена KCNJ11. Вопросы питания. 2016;85(2):61-6.
  14. Chiang YT., Ip W., Jin T. The role of the Wnt signaling pathway in incretin hormone production and function. Front Physiol. 2012;3:273. doi: 10.3389/fphys.2012.002 73.
  15. Adams J.D., Vella A. What can diabetes-associated genetic variation in TCF7L2 teach us about the pathogenesis of Type 2 diabetes? Metab Syndr Relat Disord. 2018;16:383-89. Doi: 10.1089/ met.2018.0024.
  16. Pearson E.R., Donnelly L.A., Kimber C., et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study Diab. 2007;56(8):2178-82. doi: 10.2337/db07-0440.
  17. Махрова И.А., Глотов О.С., Глебова М.А. и др. Эффективность применения метформина при ожирении и метаболическом синдроме у детей и подростков в зависимости от полиморфизма гена TCF7L2. Медицинская генетика. 2012;11(4):29-35.
  18. Srinivasan S., Kaur V, Chamarthi B., et al. TCF7L2 genetic variation augments incretin resistance and influences response to a sulfonylurea and metformin: The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH) Diab Care. 2018;41(3):554-61. doi: 10.2337/dc17-1386.
  19. Dujic T., Bego T., Malenica M., et al. Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes. Bosn J Basic Med Sci. 2019;19(4):368-74. Doi: 10.17305/ bjbms.2019.4181.
  20. Wan J., Jiang X., Bai J., et al. The effects of E23K polymorphism in Kir6.2 subunit on insulin sensitivity in skeletal muscle cells by long-chain fatty acyl CoA. Biochem Biophys Res Commun. 2009;381(4):496-501. Doi: 10.1016/j. bbrc.2009.02.070.
  21. Кукес В.Г., Сычев Д.А., Аль-Ахмед Фейсал, Дмитриев В.А. Влияние индивидуальных особенностей пациентов на риск развития нежелательных лекарственных реакций. Вестник Росздравнадзора. 2011;6:59-63.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2021